HILE(SH:603718)2018-04-25 16:00Financial Performance - Net profit attributable to shareholders decreased by 17.34% to CNY 20,614,166.42 year-on-year[6] - Operating revenue declined by 15.52% to CNY 61,780,112.64 compared to the same period last year[6] - Basic and diluted earnings per share both decreased by 25.00% to CNY 0.03[6] - Total operating revenue for the current period is ¥61,780,112.64, a decrease of 15.6% from ¥73,129,262.56 in the previous period[31] - The company reported a total profit of ¥19,534,897.82, down 18.5% from ¥23,933,435.13 in the previous period[31] Cash Flow - Net cash flow from operating activities increased by 60.55% to CNY 1,204,316.89 year-on-year[6] - The cash inflow from operating activities was 41,356,328.12 RMB, down 29% from 58,131,493.23 RMB in the previous period[41] - The net cash flow from operating activities increased to 12,797,350.17 RMB, compared to 8,946,949.85 RMB in the prior period, representing a 43% increase[41] - Cash inflow from investment activities totaled 300,806,372.18 RMB, a decrease of 32% from 445,044,972.60 RMB in the previous period[41] - The net cash flow from investment activities was -21,151,166.25 RMB, a significant decline from 135,824,832.20 RMB in the prior period[41] - The total cash and cash equivalents at the end of the period were 82,681,607.78 RMB, down from 573,845,799.98 RMB in the prior period, a decrease of 86%[41] - The company reported a cash outflow of 8,362,930.41 RMB from cash and cash equivalents, compared to an inflow of 294,770,385.83 RMB in the previous period[41] Assets and Liabilities - Total assets increased by 1.75% to CNY 1,629,800,844.07 compared to the end of the previous year[6] - Total liabilities reached CNY 537,387,015.51, compared to CNY 526,830,753.52, marking an increase of approximately 2.1%[24] - Current assets totaled CNY 841,159,882.96, up from CNY 818,474,940.60, indicating an increase of about 2.1%[23] - Non-current assets amounted to CNY 788,640,961.11, slightly rising from CNY 783,243,483.22, reflecting a growth of around 0.6%[23] - Owner's equity rose to CNY 1,092,413,828.56 from CNY 1,074,887,670.30, showing an increase of about 1.6%[24] Shareholder Information - The total number of shareholders reached 18,942 at the end of the reporting period[9] - The largest shareholder, Shanghai Haoyuan Technology Development Co., Ltd., holds 50.90% of the shares[9] Expenses - Management expenses decreased by 32.43% to CNY 15,201,203.33 from CNY 22,497,215.86, mainly due to different expense aggregation after the subsidiary commenced production[12] - Financial expenses increased by 77.28% to CNY 3,108,658.71 from CNY 1,753,565.79, mainly due to interest expenses from subsidiary borrowings[12] - Sales expenses decreased to ¥11,123,990.78 from ¥14,745,093.91, a reduction of 24.5%[31] Investment Activities - The company reported a significant decrease in investment cash flow net amount by 119.21% to -CNY 24,931,537.38, primarily due to increased financial product investments[13] - The company paid 20,603,160.40 RMB for the purchase of fixed assets, an increase from 14,220,140.40 RMB in the previous period[41] - Investment income increased significantly to ¥9,172,705.58 from ¥3,993,887.31, marking a growth of 129.5%[31] Strategic Developments - The company received approval for the production and sale of a new vaccine, which is expected to enhance market opportunities post-July 1, 2018[15] - The company plans to acquire Shanghai Jiemen Biotechnology Co., transitioning from a share issuance to a cash purchase, with due diligence and evaluation ongoing[17]